The project has been continued by Eli Lilly, a U.S. pharmaceutical company that obtained registration for IN glucagon as a powder (with beta-cyclodextrin plus dodecyl-phospho-choline as the promoter) [69,70] for severe hypoglycemia in adult and adolescent insulin users in US, Canada, and Europe in 2019. This evidence concerns the gene INS and Hypoglycemia.